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In recent years, the translation of genomic discoveries into mainstream medical practice and public health has
gained momentum, facilitated by the advent of new technologies. However, there are often major discrepancies in
the pace of implementation of genomic medicine between developed and developing/resource-limited countries.
The main reason does not only lie in the limitation of resources but also in the slow pace of adoption of the new
findings and the poor understanding of the potential that this new discipline offers to rationalize medical diagnosis
and treatment. Here, we present and critically discuss examples from the successful implementation of genomic
medicine in resource-limited countries, focusing on pharmacogenomics, genome informatics, and public health
genomics, emphasizing in the latter case genomic education, stakeholder analysis, and economics in pharmacogenomics.
These examples can be considered as model cases and be readily replicated for the wide implementation of
pharmacogenomics and genomic medicine in other resource-limited environments.
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Advances in genomics and related technologies have
revolutionized the practice of medicine by means of
better diagnosing and/or prognosing human inherited
disorders and cancer and rationalizing drug use [1].
Translation of genomic findings into health care and
health systems has been catalyzed by the advent of
genome-wide studies, in which next-generation sequen-
cing for either targeted, whole-exome, and/or whole-
genome sequence analyses stands as the most powerful
approach [2]. These approaches are gradually being
adopted by diagnostic laboratories and hospitals in the
USA and Western Europe, with several tangible results in
the context of the implementation of genomic medicine.
In addition, there are several guidelines both from the US
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creativecommons.org/publicdomain/zero/1.0/and the European Medicines Agency (EMA; http://
www.ema.europa.eu) regarding the use of genome-based
therapies.
However, the pace of implementation of genomic
medicine practices outlined above is not always equally
met in developing and resource-limited countries, where
significant barriers exist, often related to lack of tangible
resources as well as technology and knowledge transfer.
Furthermore, biomedical scientists and health care pro-
fessionals in these countries frequently fail to fully ap-
preciate the potential that this new approach offers to
improve medical diagnosis and treatment. As such and
taking into consideration that approximately 85 % of the
world’s population lives in developing/resource-limited
countries, making genomic medicine accessible in these
countries represents a major opportunity and challenge.
There have been recently some significant examples
from the successful implementation of genomic medi-
cine in resource-limited settings in Europe and Asia,
which could stand as examples for replication in similar
environments, towards a broader implementation of
genomic medicine and pharmacogenomics.ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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Successful translation of genomics into genomic medi-
cine relies on several related disciplines, such as popula-
tion genomics, pharmacogenomics, or informatics and
the approach/task of public health genomics, which are
frequently intersected. Below, we describe some exam-
ples from successful implementation of genomic medi-
cine related to these disciplines and approaches.
Development of a European-wide pharmacogenomics
map: the Euro-PGx project
The implementation rate of pharmacogenomics in the
various health systems in Europe is very heterogeneous.
This is not only due to the variable degree of har-
monization of the national guidelines within Europe, par-
ticularly related to health care and education, but also
most importantly due to differences in resource availa-
bility, making implementation of pharmacogenomics in
resource-limited European countries an even more chal-
lenging task [3]. Also, there is very little knowledge regar-
ding the pharmacogenomic biomarker allele frequencies
in various European countries, to shortlist the different
actionable pharmacogenomic biomarkers that would be
useful in clinical settings of different countries, on which
to base drug dose recommendations. The Euro-PGx
project (http://www.goldenhelix.org/index.php/research/
pharmacogenomics-in-europe) aims to determine the
varying pharmacogenomic biomarkers allele frequencies
in a large number of mostly developing European coun-
tries in an effort to produce drug dose recommendations
for different countries. Preliminary findings from a large-
scale genotyping effort using the DMET+ microarray
(Affymetrix, Santa Clara, CA, USA), including 1936 phar-
macogenomic biomarkers in 231 pharmacogenes, suggest
that the allele frequencies of several pharmacogenomic
biomarkers vary significantly among different European
countries, despite the fact that the vast majority of the
European populations have a very strong Caucasian gen-
etic component. In particular, as far as anticoagulation
treatment is concerned, significant differences were found
in allele frequencies of the CYP2C9*3 allele in the Serbian
population, while there are differences in the average war-
farin dosing in the different European countries in-
vestigated (Mizzi et al., in preparation). These varying
frequencies in the pharmacogenomic biomarkers in differ-
ent European populations will be made accessible to the
scientific community through the FINDbase database
(http://www.findbase.org) using the microattribution ap-
proach [4]. Also, in an effort to increase pharmacoge-
nomics education and awareness among health care
professionals, the Euro-PGx project coordinates the
organization of pharmacogenomics educational activities
in various European countries, namely the Golden HelixPharmacogenomics Days (http://pharmacogenomicsdays.
goldenhelix.org). Until June 2015, 15 different events have
been organized in ten European, mostly developing, coun-
tries, with the expectation to expand these activities in
other developing nations around the world.
Pharmacogenomics in clinical settings
Perhaps one of the most characteristic and noteworthy ex-
amples of success story in pharmacogenomics is the dis-
covery of the association of the HLA-B*1502 allele with
the devastating carbamazepine-induced Stevens-Johnson
Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) [5] and
of the HLA-B*5801 allele with allopurinol-induced severe
cutaneous adverse reactions [6] in Southeast Asia and
particularly in Taiwan. Subsequently, a large clinical study
conducted in Taiwan confirmed the benefit of HLA-
B*1502 testing to prevent carbamazepine-induced SJS-
TEN by using HLA-B*1502 screening to prospectively
identify subjects at genetic risk for the condition [7]. This
led the Taiwanese government to cover and reimburse the
costs for HLA-B*1502 genetic testing since 2010.
From the numerous pharmacogenomics studies con-
ducted to date, a large number of genomic biomarkers
have been shown to be correlated with variable drug effi-
cacy and/or toxicity. However, only a small fraction of
these drugs have been approved by regulatory agencies
to bear pharmacogenomic information in their labels.
To facilitate exploitation of this valuable information
from clinicians, who often lack the necessary genomics
education, it is of utmost importance to make this know-
ledge readily available in a format that can be easily digested
by clinicians. To fulfill this requirement, DruGeVar data-
base (http://drugevar.genomicmedicinealliance.org) [8] was
developed, representing an online knowledge portal for
clinical pharmacogenomics which triangulates drugs with
genes and pharmacogenomic biomarkers. This online re-
source includes those pharmacogenomic biomarkers that
have been approved by regulatory agencies and allows,
through a user-friendly data querying and visualization
interface, formulation of queries that would guide clinicians
to order the correct genetic test prior to prescribe a drug to
a patient and by this, providing an individual theranostic
service.
In addition, in order to record patients’ pharmacoge-
nomic biomarkers, a pharmacogenomic card has been
proposed in Southeast Asia and the Ramathibodi Hospital
in Thailand has launched a “pharmacogenomics” wallet
card, aiming to summarize patients’ HLA gene variant in-
formation predicting risk of developing SJS/TEN from
specific drugs, a devastating and often fatal cutaneous ad-
verse reaction [9]. Such pharmacogenomics card would be
readily expandable to more drug/pharmacogenomic bio-
markers to serve patients’ needs, depending on the medi-
cation that they receive.
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Pharmacogenetics and Pharmacogenomics (RIBEF, cre-
ated in 2006) aims to promote collaborative pharma-
cogenomics research in Iberoamerica. RIBEF currently
consists of 43 research groups and more than 200 re-
searchers with the main goals and principles to promote
scientific studies among its members and clinical imple-
mentation of pharmacogenomics to improve drug efficacy
and security with the ultimate goal of helping the health-
care needs of neglected populations. As such, the aims of
the Network are to develop human resources training, to
produce research and to disseminate information in uni-
versities and hospitals, and to promote clinical implemen-
tation of pharmacogenomics. Up to date, RIBEF teaching
programs and human resources training activities include
over 400 events all over Latin America. Also, another goal
of the RIBEF network is to develop research projects,
among which are population pharmacogenomics studies
of Iberoamerican populations. For that purpose, the
CEIBA Consortium (Consorcio Europeo e Iberoamericano
de Farmacogenética de Poblaciones) was established
among the RIBEF members (Ibero-Spain and Portugal
and Latino American Network of Pharmacogenomics)
to study population pharmacogenomics of these popula-
tions. The MESTIFAR project aimed at determining
variability of polymorphisms in genes involved in re-
sponse to drugs in populations of different ethnic origin
[Native Americans (Amerindian) and Mestizos (the result
of post-Columbian admixture)]. In total, more than 6000
healthy volunteers have been evaluated, constituting one
of the largest populations pharmacogenomics study con-
ducted today. Besides population pharmacogenomics, the
network has other ongoing projects that are related to
clinical pharmacogenomics in neurology, psychiatry, car-
diovascular and infectious diseases, etc., with up to a total
of 31 scientific articles being published so far.
In Africa, there is a disproportionate burden of disease
with the triple challenge caused by HIV/AIDS, tuber-
culosis, and malaria against a backdrop of an increasing
burden of non-communicable diseases [10]. Genomic ana-
lyses have found that several genetic variants can provide
increased resistance or susceptibility to HIV infections
[11]. Moreover, more than 80 % of therapeutic drugs used
in the management of these diseases/conditions are me-
tabolized by cytochrome P450 (CYP) enzymes that exhibit
genetic polymorphisms. Recent studies have provided evi-
dence of a huge variability in the pattern of genetic varia-
tions in the CYP genes among African populations that
was translated into differences in drug response [12].
Lastly, in the Middle East, pharmacogenomics research
started in 1996 in the United Arab Emirates (UAE), initially
involving erythrocyte glucose-6-phosphate dehydrogenase
deficiency (G-6-PD) related with drug-induced hemolytic
anemia [13] and later arylamine N-acetyltransferase(NAT2) [14]. Also, the CYP2D6 pharmacogenomic marker
allele frequencies were investigated in the Emirati popula-
tion, including reporting of four novel CYP2D6 variants
[15], while a warfarin pharmacogenomics study is cur-
rently under way for the Emirati population [16] (AlJaibeji
and coworkers; unpublished). These studies sparked an
interest from Dubai Hospital to integrate pharmacogen-
omics information for chemotherapeutic agents, while the
UAE Health Authority policy of reporting adverse drug re-
action in the UAE requires expert pharmacogenomics rec-
ommendation within the first 24 h related to each adverse
drug reactions reported [17].
Mapping of stakeholders in genomic medicine
A plethora of key players and stakeholders compose the
genomic medicine puzzle, whose level of genomics aware-
ness and views varies significantly. Systematic mapping of
the views and opinions of the various stakeholders on gen-
omic medicine would positively impact on better under-
standing the corresponding policy environment and the
role of the relevant key stakeholders in the field, on identi-
fying the main opportunities and obstacles for evidence-
informed policy-making and timely implementation in
pharmacogenomics and genomic medicine, and on priori-
tizing the various stakeholders’ needs, in an effort to better
plan the undertaking of various measures in genome-
based health care, i.e., from the perspective of public
health genomics.
Recently, Mitropoulou and coworkers undertook such
initiative to assess the level of support or opposition to
pharmacogenomics and genomic medicine in Greece
[18]. This survey indicated that the majority of the key
stakeholders, namely academic institutions and research
organizations, the bioethics council, private genetic la-
boratories, citizens, pharmaceutical and biotechnology
companies, genetics and genomics professional associa-
tions, private health insurance, industry, pharmacists,
and physicians (both geneticists and other specialties),
are highly supportive of pharmacogenomics and gen-
omic medicine in Greece. On the contrary, the Ministry
of Health and the social health insurance funds oppose
to the implementation of genomic medicine, while
the Greek National Medicines Organization displays a
neutral stance, possibly since the cost-effectiveness and
cost-benefit of a pharmacogenomics approach is not yet
fully proven, proper legislation to oversee the operation
of private genetic testing laboratories is not yet in place,
or simply because they fear that reimbursement of gen-
etic testing could increase rather than decrease the over-
all health-care expenditure. These latter stakeholders
have high intervention power against the implementa-
tion of pharmacogenomics and genomic medicine into
mainstream clinical practice. Subsequently, several op-
portunities and obstacles in the pharmacogenomics and
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from this analysis, based on the current position and
intervention potential of the key stakeholders. Similar
analysis is currently on its way in Middle Eastern coun-
tries to determine the current position and views of the
corresponding stakeholders in these countries.
Also, insufficient genomics education and lack of gen-
omics awareness among health-care professionals and
the general public are two perspectives of the same
issue, which hinders the smooth incorporation of gen-
omic medicine into clinical practice [19]. On the one
hand, the vast majority of health-care professionals state
that they feel insufficiently trained in genomics to be
able to engage with the delivery of genome-based ser-
vices [18], while on the other hand, patients and the
broader public tend to have low genomic literacy, which
impairs their capacity to successfully integrate genome-
based information into their personal decision-making,
which is a challenge for public health genomics and here
especially for the field of health literacy [20]. On top of
this, genomics education is not uniformly provided in
various academic institutions worldwide, with the USA
and Western European countries to lead the way and
the Southeastern European countries lagging behind. A
recent survey in 175 departments from 98 universities
from 11 Southeastern European countries indicated that
for a significant number of universities, the topic of
pharmacogenetics/pharmacogenomics is not included at
all in their undergraduate and postgraduate curricula in
health sciences [21]. Also, studies surveyed Greek and
Italian physicians indicated that only a small fraction of
those feel competent enough either to propose a genetic
test for their patients and/or to interpret the results from
such a test [21, 22]. These findings are in sharp contrast
with the current reality of pharmacogenomics education
in northern European countries, where pharmacogenom-
ics are more uniformly and extensively taught and high-
light the need for a more in-depth genomics education,
either with the incorporation of pharmacogenomics and
genomic medicine in their undergraduate or graduate
training, or in the form of continuous medical education
seminars. These studies might provide the basis to
harmonize pharmacogenomics education in southeast
European countries with those of northwest European
countries, such that it would directly impact on a
smoother and timely integration of pharmacogenomics
into mainstream medical practice.
As in other resource-limited regions, in Latin America
there are very few postgraduate programs focusing on
genomics [23]. Finally, in Africa, the high cost of genomic
services and low private investment is compounded by a
relatively low level of medical professionals with under-
standing of genomics [24]. In addition, a recent attempt in
sub-Saharan Africa to triangulate the views of multiplestakeholders related to sickle-cell disease (SCD), namely
doctors, parents with SCD-affected children, and adult
SCD patients towards prenatal diagnosis of SCD, showed
several discrepancies. The majority accepted the principle
of prenatal genetic diagnosis for SCD (78.7, 89.8, and
89.2 %, respectively); however, parents (62.5 %) were more
in favor of termination of SCD-affected pregnancy, than
doctors and adults patients (36.1 and 40.9 % acceptance,
respectively). These differential attitudes signal potential
value-based conflicts on the horizon and can usefully in-
form the future policy actions in the African continent, as
OMICS biotechnologies are increasingly employed in glo-
bal health [25]. Specially, there are encouraging evidence
of participation of African-based scientists in studying the
genomics of monogenic diseases [26–29] and multifac-
torial conditions [30]. These data are concretely assisting
the effective practice of genomic medicine, that is
well established in South Africa [31], in some Northern
African countries [32, 33], and recently initiated in
Central Africa [34]. In addition, regional initiatives such
as the launch of the Southern Africa Human Genome
Project by the South African government [35] have been
boosted by international funding agencies and acade-
mic institutions, through major programs such as the
Malaria Genomic Epidemiology Network (MalariaGEN)
(http://www.malariagen.net/), the Human Heredity and
Health in Africa (H3Africa) program [36], and the African
Genome Variation Project [37]. The fortunate association
of international consortia efforts will enhance the regional
and local initiatives to build the capacity in research skills
and overcome the barriers for the use of genomics to ad-
dress the disease burden of Africans.
Current populations in Latin America are charac-
terized by high and heterogeneous levels of admixture,
arising from the history of these regions and cor-
responding to different patterns of mating between in-
dividuals of Native American, European, and African
descent [38]. As an interesting international example,
the National Institute of Genomic Medicine was built in
Mexico with public funds [39], with several publications
in the fields of population genomics and medical genom-
ics [40, 41]. Other Latin American countries, such as
Brazil and Colombia, have had success in the implementa-
tion of genetic and genomic approaches for the study of
several human diseases with high epidemiological impact
in those resource-limited countries [42–45], while an
equally important element that is helping to implement
genomics in these countries is the availability of commer-
cial tests, by service providers abroad.
Next-generation sequencing and genomic medicine
The next-generation sequencing (NGS) technology, which
was introduced 8 years ago, marked the beginning of
a new era concerning the analysis of human genome
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quencing was widely used for screening variants poten-
tially causing monogenic and complex diseases which
were located in coding and regulatory genomic regions.
However, studies involving numerous genes or large gen-
omic regions were particularly challenging due to intrinsic
technical limitations (e.g., read length encompassing up to
700 base-pairs (bp) per reaction). On the contrary, the
NGS approach allows simultaneously analyzing millions
of bp in only hours, thereby facilitating large-scale explor-
ation of the human genome [1]. The first NGS studies and
many projects nowadays have been focused on resear-
ching novel recessive disease-related sequence variants,
particularly those caused by homozygous mutations. Such
variants are relatively easy to identify because most are
novel and/or are exclusively present in several members of
the same family. This allows easy screening of candidate
variants in public SNP databases and filtering them be-
tween affected and non-affected individuals from the same
family. Successful screening attempts have also been de-
scribed for monogenic dominant Mendelian disorders.
However, this approach implies more drawbacks because
heterozygous mutations (logically) occur more frequently,
thereby involving complex filtering to select potentially
deleterious mutations. NGS has not been widely used for
some complex pathologies in which several variants might
contribute towards the phenotype, because data analysis
highlights remarkable complexity, especially for simul-
taneous interactive network exploration.
Three main approaches are normally used at present.
They mainly depend on the length of the genome region
being analyzed: whole-genome sequencing (WGS), whole-
exome sequencing (WES), and custom target sequencing
microarrays (TSM) [1]. WGS is mainly used for research
purposes while WES and TSM are used for both research
and diagnosis. Most academic and private technological
platforms for the above are located in high-income
countries. This might be due to the high cost of NGS tech-
nology, such as new-generation sequencers and bioin-
formatics platforms. However, resource-limited countries
have performed interesting studies by using NGS out-Developed
Countries 
Case avail
Well-defined p
Partnership to mul
Expanding resea
Knowledge and tec
Training oppo
Fig. 1 Encouraging collaboration between developed and developing/resou
countries will benefit from training opportunities, knowledge transfer, and exp
through comparative work and multicenter projects involving cases with raresourcing services. For instance, using such NGS services in
Colombia has led to identifying novel genes and mutations
causing monogenic diseases [43, 44, 50]. Furthermore, in-
novative diagnostic approaches have been proposed for
pathologies having overlapping phenotypes and which are
caused by various genes [43, 44]. The available data re-
garding the genomes of particular mammalian species has
enabled large-scale comparative genomics approaches lea-
ding to dissecting loci related to evolution mechanisms
and potentially contributing towards human diseases [51].
Moreover, complex pathologies such as female infertility
have also been explored via NGS (Fonseca et al. in press).
Economic evaluation in pharmacogenomics
Considering the fact that genome-based drug treatment
can contribute towards the reduction of national health-
care expenditures, mostly by reducing hospitalization due
to the various adverse drug reactions, this need is more
than ever urgent, particularly in resource-limited coun-
tries, which in many cases have vast fiscal deficits [52].
Although the field of economic evaluation in genomic
medicine, pharmacogenomics, and public health geno-
mics is currently in its infancy, the majority of the eco-
nomic evaluation studies indicate that genotype-guided
therapy can be cost-effective and of high cost-benefit in
several countries. Particularly related to resource-limited
countries, initial economic evaluation studies in the Thai
population indicated that HLA-B*15:02-guided carba-
mazepine treatment is cost-effective in Thailand com-
pared to conventional treatment and can reduce the
carbamazepine-induced severe adverse drug reactions
[53, 54]. As a result, the Thai government is now pro-
viding HLA-B*15:02 testing as a standard of care, while
the same findings were reported for the Singaporean
population, when cost-effectiveness of HLA-B*1502 ge-
notyping in adult patients with newly diagnosed epilepsy
was assessed [55].
Similarly, a recent study to evaluate cost-effectiveness
of warfarin treatment in Croatian elderly ischemic
stroke patients with atrial fibrillation indicated that
97.07 over 89.12 % of patients belonging to theDeveloping
Countries
ability
opulations
ticenter studies
rch networks
hnology transfer
rtunities
rce-limited countries in the field of genomic medicine. While developing
anding research networks, developed countries are also likely to benefit
diseases or unique clinical features from well-defined populations
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respectively, did not present major complications,
while the incremental cost-effectiveness ratio of the
pharmacogenomics-based versus the control groups was
estimated at €31,225/quality-adjusted life year (QALY), in-
dicating that pharmacogenomics-guided warfarin treat-
ment may represent a cost-effective therapy option for the
management of elderly patients with atrial fibrillation who
developed ischemic stroke in Croatia [56].
Conclusions and future perspectives
Implementation of genomic medicine in resource-limited
environments will be only made possible though stronger
collaboration in genomics research between developed
and developing/resource-limited countries, which is likely
to create benefits for all parties. To this end, developing
countries will undoubtedly benefit from training oppor-
tunities, knowledge transfer, and expanding transnational
networks, while developed countries are likely to benefit
through comparative work and multicenter projects on
families with rare diseases or unique clinical features
(Fig. 1) [57].
The outcomes of the studies, outlined in the previous
paragraphs, indicate that, as far as genomic medicine is
concerned, developing countries may be resource-limited
but are also potential-rich in producing data in various
genomic medicine-related disciplines, from the perspec-
tive of public health genomics. Although this summary of
examples depicting successful implementation of genomic
medicine in resource-limited countries is far from com-
plete, it sets a paradigm for replication in other countries,
contributing towards not only acquiring more and better
insights into the requirements to implement genomic
medicine in these environments but also harmonizing the
strategies and policies for the faster and smoother adop-
tion of genomic medicine practices in the various national
health-care systems.
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